#ESCCongress #PARAGONHF European Society of Cardiology ACC México American College of Cardiology

📌Variation in Renal Function Following Transition to #SacubitrilValsartan in 👥 w/ #HeartFailure

#CardioTwitter #CardioEd #PARADIGMHF #PARAGONHF

With ⬆️ data distinguishing HFmrEF from HFrEF and HFpEF, and new release of #PARAGONHF with subgroup analysis showing benefit if LVEF <= 57% (22%, consistent with #PARADIGMHF & #PIONEERHF ), is it time to see #Entresto HF outcomes studied in #HFmrEF ? #ESCcongress2019 #ACCPCardPRN

Is there hope for sacubitril/valsartan in #HFPEF ? Exploratory analysis suggests women do benefit #PARAGONHF #AHA19

📌Making the Case for an Expanded Indication for #SacubitrilValsartan in #HeartFailure
🔸Greater benefit at lower #LVEF in #PARAGONHF
#CardioEd #CardioTwitter

Should polypharmacy dissuade treatment optimization in heart failure?

No.

Hot off the press data suggest efficacy is sustained (maybe even better!) among those on a large # of background medicines.

#ARNI in #PARAGONHF (L) & #SGLT2i in #DELIVER (R)

👇🏾

Now out in Journal of Cardiac Failure, we describe the treatment effects of sac/val vs. val in patients with recent HF hosp in #PARAGONHF . Treatment benefits appear similar in those with lower (≤57%) vs. higher (>57%) EF. Potential implications for the ongoing #PARAGLIDEHF trial.

📌Probabilistic Readjudication of #HeartFailure Hospitalization Events in the #PARAGONHF Study
#CardioEd

Renal effect of ARNI in 👥with HF (PARADIGM-HF& PARAGONHF) via #eSPACEHF @eSPACEHF Dr Faiez Zannad

#TWILIGHT #DAPAHF #PARAGONHF #PARADIGMHF #COLCOT #PAH

Conclusiones de Julio sobre el estudio #PARAGONHF

paragonhf.secardiologia.es

Frustrating results from #PARAGONHF

Did the use of an active comparator (a ubiquitous but unproven rx in HFpEF) hamstring the experiment?

Stuart Connolly provides excellent commentary at #ESCCongress

Got new workout clothes and could not stop thinking about this.👇🏼🤦🏼‍♀️💕 #PARAGONHF

Does the fragility index hold true results
of Paragon HF? Come find out at our poster session #21 now! HFSA #HFSA2023 #paragonHF

Actualités dans l’insuffisance cardiaque au programme de ce soir avec les résultats de #PARAGONHF qui frôlent la significativité dans l’ICFEP et de #DAPAHF qui apportent un nouvel espoir dans l’ICFER
#ESC Congress #ESC congress2019 #WCC #cardiotwitter #ESC #Paris

#SimPub with European Society of Cardiology #HeartFailure2022 in Circulation

How does health status change before & after a HF 🏥?

Protocolized serial #KCCQ in #PARADIGMHF & #PARAGONHF uncovered worsening health status in months prior to HF🏥 with only partial recovery after

ahajournals.org/doi/10.1161/CI…

Continuous #heartFailure spetrum and #phenommaping as possible tools for depicting #sacubitril /valsartan response
Could Subphenotyping #HFpEF by #PulmonaryHypertension (with #diastolicdysfunction or #mitralregurgitation ) alter #PARAGONHF results?
#ESCCongress #WCC2019 #ESCCoT

New data from #PARAGONHF : Worsening #HeartFailure events (even when treated in ambulatory settings) are prognostically meaningful & should be considered in future RCTs in #HFpEF . bit.ly/3vCNslh

#JACCHF #CardioTwitter #MedTwitter #HFrEF

New paper by⭐️Brigham & Women's CV Fellows Maria A. Pabón, MD & Jon Cunningham in #EJHF on #HF RCT design

#PARAGONHF did not initially require all pts to have ↑ #NPs , but an early amendment standardized this requirement, leading to >60% ↑ events & the RCT to finish sooner.

onlinelibrary.wiley.com/doi/10.1002/ej…

#ACC24 #SimPub by Alberto Foà in JACC Journals

Fascinating observation from #PARAGONHF — pts w LVEF above 60% were at *higher* risk of hypotension & *lower* likelihood of benefit w #ARNI sacubitril/valsartan

Reinforces current guidance for pt selection

jacc.org/doi/10.1016/j.…